Results for this period
Third quarter1 October 2025 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
In the Medical Support business, the number of blood-derived processing orders, partner clinics and commissioned processing orders increased against a backdrop of growing demand, while the Company advanced service enhancement and operational efficiency initiatives. In the D2C business, the Company worked to cross-sell to existing customers, expand sales through mall channels, which offer a high-margin business model, and improve operational efficiency through the introduction of AI bots. Overall, the shift toward higher-margin businesses, transformation of the business portfolio and progress in initiatives to improve the earnings structure boosted performance.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 October 2025 to 30 June 2026 |
| Net Sales | ¥2,039 million (YoY +54.9%) |
| Operating profit | ¥415 million |
| Ordinary income | ¥409 million |
| Profit attributable to owners of the parent | ¥392 million |
| Net income per share | ¥110.92 |
| Equity ratio | End of the current fiscal period 67.8% / End of previous period 65.1% |
| Total assets | ¥3,683 million |
| Net assets | ¥2,511 million |
| Full-year earnings forecast | Net Sales ¥2,750 million (YoY +40.2%) / Operating profit ¥560 million (YoY +271.0%) / Ordinary income ¥550 million (YoY +260.9%) / Net income ¥410 million (YoY +829.9%) |
| Revision to Earnings Forecast | Net Sales Not disclosed → ¥2,750 million / Operating profit Not disclosed → ¥560 million / Ordinary income Not disclosed → ¥550 million / Net income Not disclosed → ¥410 million |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | Segment Medical Support Business / Net Sales ¥1,312,291 thousand / Year on year against the same period last year 128.5, Segment D2C Business / Net Sales ¥543,927 thousand / Year on year against the same period last year -26, Segment Other (overseas business and outside reportable segments) / Net Sales ¥182,859 thousand / Year on year against the same period last year 2,357.6 |
| Segment profit | Segment Medical Support Business / Segment profit ¥332,920 thousand / Year on year against the same period last year 1,705.4, Segment D2C Business / Segment profit ¥237,741 thousand / Year on year against the same period last year 8, Segment Other (overseas business and outside reportable segments) / Segment profit ¥126,347 thousand / Year on year against the same period last year Not disclosed |
| Depreciation and amortization | ¥11,417 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | Newly consolidated: 0 companies; excluded: 0 companies (company names: —) |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Not disclosed |
| Issued Shares at Period-End | 3,663,068 shares |
| Treasury Shares at Period-End | 100,023 shares |
| Factors Behind Changes in Business Performance | In the Medical Support business, the number of blood-derived processing orders, partner clinics and commissioned processing orders increased against a backdrop of growing demand, while the Company advanced service enhancement and operational efficiency initiatives. In the D2C business, the Company worked to cross-sell to existing customers, expand sales through mall channels, which offer a high-margin business model, and improve operational efficiency through the introduction of AI bots. Overall, the shift toward higher-margin businesses, transformation of the business portfolio and progress in initiatives to improve the earnings structure boosted performance. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Medical Support business expanded its number of partner medical institutions and commissioned processing orders, building recurring revenue. In addition, the Company advanced service enhancement and operational efficiency initiatives, strengthened sales to existing customers and restrained advertising investment in the D2C business, and introduced AI bots. These initiatives supported a shift toward higher-margin businesses and improved the earnings structure.